000			02992nam a22003495i 4500
999			_c76938 _d76938 _x1
001			76938
003			ES-MaUEC
005			20230207040245.0
007			cr nn 008mamaa
008			140519s2014 ne | s |||| 0|eng d
020			_a9789401788199
024	7		_a10.1007/978-94-017-8819-9 _2doi
040			_dES-MaUEC
050		4	_aQH588.S83 _bZ436 2014
100	1		_aZhao, Xiaoyang. _945294
245	1	0	_aStudies of Pluripotency in Embryonic Stem Cells and Induced Pluripotent Stem Cells _cby Xiaoyang Zhao.
260			_aDordrecht, Netherlands _bSpringer International Publishing _c2014
300			_a1 recurso en línea (XV, 92 p.) _b21 ilustraciones, 18 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aSpringer Theses, Recognizing Outstanding Ph.D. Research _x2190-5053
505	0		_aAbstract -- Introduction -- Establishment of highly efficient somatic cell reprogramming system to generate iPSC lines- Establishment of highly efficient somatic cell reprogramming system and establishment of iPSC lines -- Pluripotency of iPSC and underlining mechanism -- Developmental potential of mouse iPSC -- Conclusions.
520			_aStem cells have the ability to differentiate into all types of cells within the body, thus have great therapeutic potential for regenerative medicine to treat complicated disorders, like Parkinsonâ€{u3824}isease and spinal cord injury. There will also be many applications in drug development. However, several roadblocks, such as safety issues and low efficiency of pluripotent stem cell (PSC) line derivation need to be resolved before their clinical application. This thesis focuses on these two areas, so as to find methods to overcome the limitation. It covers deriving embryonic stem cells (ESCs) from several different species, and reports an efficient system to generate induced pluripotent stem cells (iPSCs), and the first iPSC mice in the world. The results in this thesis confirm that somatic cells can be fully reprogrammed with the four Yamanaka factors. In addition, we have found that the Dlk1-Dio3 region can be a potential molecular marker to distinguish the fully reprogrammed iPSCs from partially reprogrammed ones. All of these results will help improve the safety of PSCs in the clinical applications, and increase the current low induction efficiency of their production.
650		7	_2embne _aCélulas madre _9160528
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-94-017-8819-9 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12825566 _b10-10-17 _c01-10-14
942			_2lcc _cLE
945			_aQH588.S83 Z436 2014 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11554770 _z06-04-17
988			_aEBSPRINGER
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _gne _h0